search
Back to results

Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response

Primary Purpose

Asthma

Status
Completed
Phase
Phase 2
Locations
United Kingdom
Study Type
Interventional
Intervention
TD-8236
Placebo
Sponsored by
Theravance Biopharma
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring TD-8236, Asthma, Proof of concept

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female, 18 to 65 years of age
  • Willing and able to give informed consent and comply with study requirements
  • Documented physician-diagnosed asthma for ≥ 4 months prior to Screening
  • Body mass index (BMI) ≥ 18.0 and ≤ 35.0 kg/m2 at Screening and weighs ≥ 50 kg at Screening.
  • Women of child bearing potential must have a negative pregnancy test
  • Males and females must use a highly efficient birth control method
  • Pre-bronchodilator FEV1 ≥ 70% predicted
  • Documented allergy to at least one common allergen
  • Dual responder to inhaled bronchial challenges
  • Additional inclusion criteria apply

Exclusion Criteria:

  • Positive for hepatitis A, B or C, HIV or tuberculosis
  • Clinically significant abnormalities of laboratory evaluations
  • Have abnormal ECG measurements
  • Any sign of respiratory tract infection within 6 weeks of screening
  • Have a current bacterial, parasitic, fungal or viral infection
  • History of life-threatening asthma
  • Uses or have used tobacco or nicotine-containing products within 6 months prior to screening
  • Additional exclusion criteria apply

Sites / Locations

  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

TD-8236 Dose A (low dose)

TD-8236 Dose B (high dose)

Placebo

Arm Description

TD-8236 Dose A (QD x 14 days)

TD-8236 Dose B (QD x 14 days)

Placebo (QD x 14 days)

Outcomes

Primary Outcome Measures

Area Under the Curve of Change From Baseline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14
Values are reported as a weighted mean derived by calculating the AUC change from baseline over the relative time interval, divided by the time interval.

Secondary Outcome Measures

Area Under the Curve of Percentage Change From Baseline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14
Values are reported as a weighted mean derived by calculating the AUC percentage change from baseline over the relative time interval, divided by the time interval.
Maximum Decline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14
Maximum Percentage Decline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14
Area Under the Concentration-time Curve Over One 24-hour Dosing Interval (AUC0-24) of TD-8236 in Plasma
Maximum Observed Plasma Concentration (Cmax) of TD-8236 in Plasma During Dosing Interval
Time to Maximum Observed Concentration (Tmax) of TD-8236 in Plasma Over a Dosing Interval
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
A TEAE was defined as any adverse event (AE) that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus the number of days in the follow-up period. The severity of TEAEs were also assessed and were classified as mild, moderate or severe per the definitions below: Mild - The AE is noticeable to the participant and/or the investigator, but does not interfere with routine activity. Moderate - The AE interferes with routine activity, but responds to symptomatic therapy or rest. Severe - The AE significantly limits the participant's ability to perform routine activities despite symptomatic therapy.

Full Information

First Posted
October 15, 2019
Last Updated
February 17, 2022
Sponsor
Theravance Biopharma
search

1. Study Identification

Unique Protocol Identification Number
NCT04150341
Brief Title
Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response
Official Title
A Randomized, Double-blind, Placebo-controlled, 3-period Crossover Study to Evaluate the Effects of Repeated Doses of Inhaled TD-8236 and Impact on Airway Responses Following Allergen Challenge in Patients With Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Completed
Study Start Date
November 6, 2019 (Actual)
Primary Completion Date
August 28, 2020 (Actual)
Study Completion Date
September 3, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Theravance Biopharma

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This will be a randomized, double-blind, placebo-controlled study. The study will use a three-period, six-sequence, complete-block, cross-over study design to characterize two doses of inhaled TD-8236 compared to placebo in subjects with mild asthma and a known response to an allergen. Each of the three periods will be 14 days, followed by a washout period before the next period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
TD-8236, Asthma, Proof of concept

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
TD-8236 Dose A (low dose)
Arm Type
Experimental
Arm Description
TD-8236 Dose A (QD x 14 days)
Arm Title
TD-8236 Dose B (high dose)
Arm Type
Experimental
Arm Description
TD-8236 Dose B (QD x 14 days)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo (QD x 14 days)
Intervention Type
Drug
Intervention Name(s)
TD-8236
Intervention Description
The study drug will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
The placebo will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
Primary Outcome Measure Information:
Title
Area Under the Curve of Change From Baseline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14
Description
Values are reported as a weighted mean derived by calculating the AUC change from baseline over the relative time interval, divided by the time interval.
Time Frame
Day 14 of treatment period: 3 to 8 hours after allergen challenge
Secondary Outcome Measure Information:
Title
Area Under the Curve of Percentage Change From Baseline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14
Description
Values are reported as a weighted mean derived by calculating the AUC percentage change from baseline over the relative time interval, divided by the time interval.
Time Frame
Day 14 of treatment period: 3 to 8 hours after allergen challenge
Title
Maximum Decline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14
Time Frame
Day 14 of treatment period: 3 to 8 hours after allergen challenge
Title
Maximum Percentage Decline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14
Time Frame
Day 14 of treatment period: 3 to 8 hours after allergen challenge
Title
Area Under the Concentration-time Curve Over One 24-hour Dosing Interval (AUC0-24) of TD-8236 in Plasma
Time Frame
Day 14 of treatment period: Pre-dose and 0.5, 1, 2, 4, 6, 8 and 24 hours post-dose
Title
Maximum Observed Plasma Concentration (Cmax) of TD-8236 in Plasma During Dosing Interval
Time Frame
Day 14 of treatment period: Pre-dose and 0.5, 1, 2, 4, 6, 8 and 24 hours post-dose
Title
Time to Maximum Observed Concentration (Tmax) of TD-8236 in Plasma Over a Dosing Interval
Time Frame
Day 14 of treatment period: Pre-dose and 0.5, 1, 2, 4, 6, 8 and 24 hours post-dose
Title
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
Description
A TEAE was defined as any adverse event (AE) that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus the number of days in the follow-up period. The severity of TEAEs were also assessed and were classified as mild, moderate or severe per the definitions below: Mild - The AE is noticeable to the participant and/or the investigator, but does not interfere with routine activity. Moderate - The AE interferes with routine activity, but responds to symptomatic therapy or rest. Severe - The AE significantly limits the participant's ability to perform routine activities despite symptomatic therapy.
Time Frame
Day 1 to end of follow-up (up to approximately 98 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female, 18 to 65 years of age Willing and able to give informed consent and comply with study requirements Documented physician-diagnosed asthma for ≥ 4 months prior to Screening Body mass index (BMI) ≥ 18.0 and ≤ 35.0 kg/m2 at Screening and weighs ≥ 50 kg at Screening. Women of child bearing potential must have a negative pregnancy test Males and females must use a highly efficient birth control method Pre-bronchodilator FEV1 ≥ 70% predicted Documented allergy to at least one common allergen Dual responder to inhaled bronchial challenges Additional inclusion criteria apply Exclusion Criteria: Positive for hepatitis A, B or C, HIV or tuberculosis Clinically significant abnormalities of laboratory evaluations Have abnormal ECG measurements Any sign of respiratory tract infection within 6 weeks of screening Have a current bacterial, parasitic, fungal or viral infection History of life-threatening asthma Uses or have used tobacco or nicotine-containing products within 6 months prior to screening Additional exclusion criteria apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Theravance Biopharma
Official's Role
Study Director
Facility Information:
Facility Name
Theravance Biopharma Investigational Site
City
London
ZIP/Postal Code
W1G 8HU
Country
United Kingdom
Facility Name
Theravance Biopharma Investigational Site
City
Manchester
ZIP/Postal Code
M23 9QZ
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.

Learn more about this trial

Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response

We'll reach out to this number within 24 hrs